Fosun Pharma Q1 Net Profit Reaches 871 Million Yuan, Up 13.87% Year-on-Year

Fosun Pharma Posts Steady Q1 Growth

According to 36Kr, Fosun Pharmaceutical recently released its first-quarter 2026 earnings report. The company recorded operating revenue of 10.073 billion yuan, up 6.93% year-on-year; net profit attributable to shareholders of the listed company reached 871 million yuan, a 13.87% year-on-year increase; and basic earnings per share came in at 0.33 yuan. Revenue surpassed the 10-billion-yuan mark in a single quarter for the first time, signaling a positive growth trajectory.

Key Financial Highlights

From a financial perspective, Fosun Pharma demonstrated strong profitability this quarter. Net profit growth significantly outpaced revenue growth, indicating continued optimization in cost control and operational efficiency. The 13.87% year-on-year increase in net profit is a commendable performance given the overall pressure facing the pharmaceutical industry.

Specifically:

• Operating Revenue: 10.073 billion yuan, up 6.93% year-on-year
• Net Profit Attributable to Shareholders: 871 million yuan, up 13.87% year-on-year
• Basic Earnings Per Share: 0.33 yuan

Profit growth nearly doubled the pace of revenue growth, reflecting continued improvement in the company's product mix and an increasing share of high-margin innovative drugs.

AI-Powered Pharmaceutical Innovation Emerges as New Growth Engine

Notably, Fosun Pharma's strategic positioning in the AI-plus-pharma space in recent years is gradually entering a harvest phase. The company has continued to increase investment in AI-assisted drug development, intelligent manufacturing, and digital marketing, leveraging artificial intelligence to accelerate drug discovery and clinical trial processes, effectively shortening R&D cycles and reducing development costs.

In AI-driven drug development, Fosun Pharma has actively partnered with multiple AI biotech companies, utilizing deep learning and big data analytics for target discovery, molecular design, and clinical prediction. This integrated "AI plus traditional pharma" model is becoming a key driver behind the company's improving profit margins.

Additionally, in smart healthcare and digital transformation, Fosun Pharma is accelerating its deployment in cutting-edge areas such as intelligent diagnostics and AI-powered medical imaging analysis, aiming to build a comprehensive digital system covering the entire chain from R&D to production, distribution, and end-user delivery.

Industry Context and Future Outlook

The global pharmaceutical industry is currently undergoing profound transformation, and the deep integration of AI technology with biopharmaceuticals has become an industry-wide consensus. According to market research firms, the global AI-driven pharmaceutical market is expected to exceed 10 billion U.S. dollars in 2026, with Chinese companies rapidly gaining competitiveness in this space.

For Fosun Pharma, the strong first-quarter performance has laid a solid foundation for full-year results. On the policy front, the Chinese government continues to encourage pharmaceutical innovation and digital transformation, providing a favorable external environment for corporate development. Looking ahead, as AI applications in drug development deepen and the innovative drug pipeline progresses toward commercialization, Fosun Pharma's growth potential warrants sustained market attention.

However, intensifying industry competition, the impact of volume-based procurement policies, and global geopolitical uncertainties remain challenges the company must navigate. Balancing the stability of traditional businesses while accelerating AI-driven innovation and transformation will be a critical priority for Fosun Pharma in the next phase.